Ovoca Bio Plc Logo

Ovoca Bio Plc

Biopharma developing a novel therapy for premenopausal women with low sexual desire (HSDD).

OVXA | IR

Overview

Corporate Details

ISIN(s):
IE0006649010 (+1 more)
LEI:
213800ST2AK5XQ1O5207
Country:
Ireland
Address:
17 PEMBROKE STREET UPPER, D02 AT22 DUBLIN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Ovoca Bio Plc is a clinical-stage biopharmaceutical company focused on developing novel treatments for women's health. The company's lead product candidate is Orenetide, a medicinal therapy for premenopausal women with hypoactive sexual desire disorder (HSDD), a condition with significant unmet medical need. Ovoca Bio is advancing Orenetide through clinical development and regulatory approval processes in the US, Europe, and other major global markets. The company's strategy involves leveraging its protective patent portfolio and seeking commercialization through licensing agreements and collaborations with pharmaceutical partners.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-30 14:09
Report Publication Announcement
Replacement Half Year Report
English 10.8 KB
2025-06-05 08:00
Delisting Announcement
Delisting from Euronext Growth Exchange
English 9.0 KB
2025-03-03 15:00
Board/Management Information
Management Changes
English 8.0 KB
2024-12-18 19:00
Post-Annual General Meeting Information
Result of AGM
English 7.1 KB
2024-11-18 08:00
Pre-Annual General Meeting Information
Notice of AGM
English 7.0 KB
2024-10-11 18:30
Major Shareholding Notification
Holding(s) in Company
English 6.8 KB
2024-10-09 18:45
Transaction in Own Shares
Sale of Treasury Shares
English 6.0 KB
2024-09-25 08:00
Report Publication Announcement
Half-year Report
English 7.6 KB
2024-09-02 15:30
Related Party Transaction
Consultancy Agreement
English 8.7 KB
2024-07-15 08:00
Director's Dealing
Director/PDMR Shareholding
English 27.4 KB
2024-07-15 08:00
Board/Management Information
Directorate Change
English 8.8 KB
2024-06-28 08:00
Report Publication Announcement
Annual Financial Report
English 14.5 KB
2024-06-20 00:00
Annual Report
English 1.2 MB
2024-01-23 08:00
Major Shareholding Notification
Holding(s) in Company
English 7.9 KB
2023-12-01 13:00
Post-Annual General Meeting Information
Result of AGM
English 7.8 KB

Automate Your Workflow. Get a real-time feed of all Ovoca Bio Plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ovoca Bio Plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ovoca Bio Plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Corline Biomedical AB Logo
Develops heparin-based coatings for medical device biocompatibility and regenerative medicine.
Sweden CLBIO
Cosma Spolka Akcyjna Logo
Produces natural hemp supplements and pharmaceutical raw materials for retail & wholesale markets.
Poland COS
COSMO Pharmaceuticals N.V. Logo
Specialty pharma for gastroenterology/dermatology, offering colon treatments & manufacturing services.
Netherlands COPN
Crossject Logo
Develops needle-free auto-injectors for rapid drug delivery in medical emergencies.
France ALCJ
CTC BIO, INC. Logo
Develops pharmaceuticals and feed additives for human and animal health using fermentation tech.
South Korea 060590
Cuorips Inc. Logo
Develops iPS cell therapies, like a cardiomyocyte sheet for severe heart failure.
Japan 4894
curacle co., ltd. Logo
Developing drugs for intractable diseases like diabetes caused by vascular damage and aging.
South Korea 365270
Curevac Logo
Pioneering mRNA technology to create vaccines and therapies for infectious diseases, cancer, and more.
Germany CVAC
Curocell Inc. Logo
Biotech developing enhanced CAR-T therapies for cancer using its OVIS™ platform.
South Korea 372320
Cyfuse Biomedical K.K. Logo Japan 4892

Talk to a Data Expert

Have a question? We'll get back to you promptly.